Literature DB >> 1884169

A history of boron neutron capture therapy of brain tumours. Postulation of a brain radiation dose tolerance limit.

D N Slatkin1.   

Abstract

Boron neutron capture therapy (BNCT) is a form of radiation therapy mediated by the short-range (less than 10 microns) energetic alpha (4He) and lithium-7 (7Li) ionizing particles that result from the prompt disintegration by slow neutrons of the stable (nonradioactive) nucleus boron-10 (10B). Recent advances in radiobiological and toxicological evaluation of tumour-affinitive boron-containing drugs and in optimization of the energies of neutrons in the incident beam have spurred interest in BNCT. This article presents a history of BNCT that emphasizes studies in the USA. A new dosimetric analysis of the 1959-1961 clinical trials of BNCT at Brookhaven National Laboratory is also presented. This analysis yields an acute radiation dose tolerance limit estimate of approximately 10 Gy-Eq to the capillary endothelium of human basal ganglia from BNCT. (Gy-Eq: Gray-equivalent, or relative biological effectiveness of a radiation component multiplied by the physical dose of the component (Gy), summed over the component kinds of radiation.)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884169     DOI: 10.1093/brain/114.4.1609

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  23 in total

1.  Organisation and management of the first clinical trial of BNCT in Europe (EORTC protocol 11961).EORTC BNCT study group.

Authors:  W Sauerwein; R Moss; J Rassow; F Stecher-Rasmussen; K Hideghéty; J G Wolbers; H Sack
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

2.  Tolerance of the normal canine brain to epithermal neutron irradiation in the presence of p-boronophenylalanine.

Authors:  J A Coderre; P R Gavin; J Capala; R Ma; G M Morris; T M Button; T Aziz; N S Peress
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 3.  Common challenges and problems in clinical trials of boron neutron capture therapy of brain tumors.

Authors:  N Gupta; R A Gahbauer; T E Blue; B Albertson
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

4.  New drugs for BNCT: an experimental approach.

Authors:  L Weissfloch; M Bremer; P Lemmen; T Probst; M Wagner; M Peller; T Auberger; R Senekowitsch-Schmidtke; K Tempel; M Molls
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

5.  The combination of boron neutron-capture therapy and immunoprophylaxis for advanced intracerebral gliosarcomas in rats.

Authors:  H M Smilowitz; P L Micca; M M Nawrocky; D N Slatkin; W Tu; J A Coderre
Journal:  J Neurooncol       Date:  2000       Impact factor: 4.130

6.  Synthesis and Applications of Perfunctionalized Boron Clusters.

Authors:  Jonathan C Axtell; Liban M A Saleh; Elaine A Qian; Alex I Wixtrom; Alexander M Spokoyny
Journal:  Inorg Chem       Date:  2018-02-21       Impact factor: 5.165

7.  Effect of dose and infusion time on the delivery of p-boronophenylalanine for neutron capture therapy.

Authors:  D D Joel; J A Coderre; P L Micca; M M Nawrocky
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

Review 8.  Early history of development of boron neutron capture therapy of tumors.

Authors:  W H Sweet
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

9.  Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy.

Authors:  Atsushi Doi; Shinji Kawabata; Kyoko Iida; Kunio Yokoyama; Yoshinaga Kajimoto; Toshihiko Kuroiwa; Takashi Shirakawa; Mitsunori Kirihata; Satoshi Kasaoka; Kazuo Maruyama; Hiroaki Kumada; Yoshinori Sakurai; Shin-Ichiro Masunaga; Koji Ono; Shin-Ichi Miyatake
Journal:  J Neurooncol       Date:  2008-01-25       Impact factor: 4.130

10.  Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view.

Authors:  Aidnag Z Diaz
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.